363 related articles for article (PubMed ID: 19091906)
1. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
[TBL] [Abstract][Full Text] [Related]
2. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.
Aerts HJ; Dubois L; Hackeng TM; Straathof R; Chiu RK; Lieuwes NG; Jutten B; Weppler SA; Lammering G; Wouters BG; Lambin P
Radiother Oncol; 2007 Jun; 83(3):326-32. PubMed ID: 17531336
[TBL] [Abstract][Full Text] [Related]
4. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
5. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats.
Samén E; Arnberg F; Lu L; Olofsson MH; Tegnebratt T; Thorell JO; Holmin S; Stone-Elander S
J Nucl Med; 2013 Oct; 54(10):1804-11. PubMed ID: 24003078
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.
Sadri K; Ren Q; Zhang K; Paudyal B; Devadhas D; Rodeck U; Thakur M
Nucl Med Commun; 2011 Jul; 32(7):563-9. PubMed ID: 21572364
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
[TBL] [Abstract][Full Text] [Related]
10. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM
Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
[TBL] [Abstract][Full Text] [Related]
12. Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.
Even AJ; Hamming-Vrieze O; van Elmpt W; Winnepenninckx VJ; Heukelom J; Tesselaar ME; Vogel WV; Hoeben A; Zegers CM; Vugts DJ; van Dongen GA; Bartelink H; Mottaghy FM; Hoebers F; Lambin P
Oncotarget; 2017 Jan; 8(3):3870-3880. PubMed ID: 27965472
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.
Garousi J; Andersson KG; Mitran B; Pichl ML; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Apr; 48(4):1325-32. PubMed ID: 26847636
[TBL] [Abstract][Full Text] [Related]
14. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
15. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
16. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract][Full Text] [Related]
17. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
18. Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy.
Rades D; Wolff C; Nadrowitz R; Breunig C; Schild SE; Baehre M; Meller B
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1226-31. PubMed ID: 19356858
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
20. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
